Search for a trial

A randomized trial to increase the efficiency of the prevention of contrast induced acute kidney injury.
The Compass trial

To study whether the existing eGFR cut-off levels for preventive hydration of < 45 ml/min or between 45-60 ml/min in combination of other comorbidity at risk of CIN can be safely lowered to an eGFR < 30 ml/min, regarsless of the…

A study to assess the anti-albuminuric effects and variability in response to dapagliflozin in subjects with type 2 diabetes

Primary Objective: To assess the change from baseline in 24-hr albuminuria with dapagliflozin for six weeks relative to placebo treatment in patients with diabetes and albuminuria > 100 mg/day on stable ACEi or ARB treatment.Secondary…

A Double-Blind clinical trial of Benfotiamine Treatment in Diabetic Nephropathy

-To investigate whether a short-term treatment (3 months) with benfotiamine in diabetic nephropathy patients leads to a reduction in urinary excretion of β2-microglobulin and albumin.-To investigate whether short-term treatment (3 months) with…

A single-center, prospective, placebo-controlled, double-blind, randomized, cross-over mechanistic intervention study to investigate the effect of empagliflozin on kidney function in people with either preserved or impaired kidney function with or without type 2 diabetes

We aim to investigate the renal hemodynamic effects of empagliflozin in people with either preserved or impaired renal function with T2DM and people with impaired renal function without T2DM, all with and without adenosine blockade.

A phase 4, monocenter, randomized, double-blind, placebo-controlled, 4-armed cross-over mechanistic intervention study to assess the renal hemodynamic effect of mono- and combination therapy with empagliflozin (SGLT-2 inhibitor) and losartan (RAS inhibitor) in metformin and/or SU-treated patients with type 2 diabetes mellitus

Investigate the effects of 7 (+-1) days of of mono- and combination therapy with the SGLT2 inhibitor empagliflozin (10 mg QD) and RAS inhibitor losartan (50 mg QD) on renal hemodynamics, (glomerular filtration rate (GFR) / effective renal plasma…

A Randomized, Multicenter, Double-Blind, Parallel, Placebo-Controlled Study of the
Effects of Canagliflozin on Renal Endpoints in Adult Subjects With Type 2 Diabetes
Mellitus ('CANVAS-R')

Primary objectiveIn subjects with T2DM receiving standard of care but with inadequate glycemic control and at elevatedrisk of cardiovascular (CV) events to assess the effect of canagliflozin compared to placebo onprogression of albuminuria.Secondary…

Parallel-Group, Placebo-Controlled Randomized Study Investigating the Effect of Intravenous Iso-osmolar Iodinated Contrast Material Iodixanol (Visipaque* Injection 320 mgI/mL) on Renal Function in Adults with Chronic Kidney Disease (CKD) Stage III or Stage IV Who Have Undergone Endovascular Aneurysm Repair (EVAR)

Primary Objective:* To demonstrate the safety of intravenous (i.v.) iodinated iso-osmolar iodixanol (Visipaque* Injection 320 mgI/mL) usage in contrast-enhanced computed tomography (CECT) for CKD stage III/IV patients by evaluating the incidence of…